Efficacy, pharmacokinetics and safety of iscalimab (CFZ533) in patients with proliferative lupus nephritis: a randomised, double-blind, placebo-controlled, phase II study

Background Iscalimab (CFZ533) is a novel, anti-CD40 monoclonal antibody. This study evaluated the efficacy, pharmacokinetics and safety of iscalimab versus placebo as add-on to standard-of-care (SoC) therapy in patients with biopsy-proven active proliferative lupus nephritis (LN).Methods This was a...

Full description

Saved in:
Bibliographic Details
Main Authors: Renaud Felten, Nan Shen, Julia Weinmann-Menke, Ana Malvar, Peter Gergely, Tamas Shisha, Carole Sips, André Serra-Roma, Markus Weiss, Rambabu Danekula, Jan Rohr
Format: Article
Language:English
Published: BMJ Publishing Group 2025-08-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/11/3/e005557.full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849390500183801856
author Renaud Felten
Nan Shen
Julia Weinmann-Menke
Ana Malvar
Peter Gergely
Tamas Shisha
Carole Sips
André Serra-Roma
Markus Weiss
Rambabu Danekula
Jan Rohr
author_facet Renaud Felten
Nan Shen
Julia Weinmann-Menke
Ana Malvar
Peter Gergely
Tamas Shisha
Carole Sips
André Serra-Roma
Markus Weiss
Rambabu Danekula
Jan Rohr
author_sort Renaud Felten
collection DOAJ
description Background Iscalimab (CFZ533) is a novel, anti-CD40 monoclonal antibody. This study evaluated the efficacy, pharmacokinetics and safety of iscalimab versus placebo as add-on to standard-of-care (SoC) therapy in patients with biopsy-proven active proliferative lupus nephritis (LN).Methods This was a phase II, randomised, double-blind, placebo-controlled, multicentre study including patients with a diagnosis of systemic lupus erythematosus with active LN. Patients were randomly assigned (2:1) to receive either intravenous iscalimab (10 mg/kg) or placebo for 24 weeks on top of SoC for LN. The primary efficacy endpoint was the ratio from baseline in urinary protein-to-creatinine ratio (UPCR) at week 24. Safety assessments included adverse events (AEs) and serious AEs (SAEs) during treatment and follow-up up to 49 weeks.Findings Of the 57 patients (iscalimab, n=39; placebo, n=18) randomised, 31 (54.4%) completed the study. The primary efficacy endpoint was met: at week 24, the relative improvement from baseline in proteinuria (UPCR) was 63.1% and 36.3% in the iscalimab and placebo arms, respectively. UPCR to baseline at week 24 showed a statistically significant reduction of 42.1% in the iscalimab versus placebo arm. Most AEs were of mild to moderate severity in both treatment arms. Overall, seven SAEs were reported in six patients (15.4%) in the iscalimab arm versus four in three patients (16.7%) in the placebo arm.Interpretation Iscalimab showed a significant improvement in proteinuria (UPCR) in patients with active LN. Iscalimab was generally well tolerated with the exception of a few severe infections and one case of macrophage-activation syndrome in immunosuppressed and comorbid patients.Trial registration number NCT03610516.
format Article
id doaj-art-e17706e3e0954a379fdee56a70bce3d3
institution Kabale University
issn 2056-5933
language English
publishDate 2025-08-01
publisher BMJ Publishing Group
record_format Article
series RMD Open
spelling doaj-art-e17706e3e0954a379fdee56a70bce3d32025-08-20T03:41:36ZengBMJ Publishing GroupRMD Open2056-59332025-08-0111310.1136/rmdopen-2025-005557Efficacy, pharmacokinetics and safety of iscalimab (CFZ533) in patients with proliferative lupus nephritis: a randomised, double-blind, placebo-controlled, phase II studyRenaud Felten0Nan Shen1Julia Weinmann-Menke2Ana Malvar3Peter Gergely4Tamas Shisha5Carole Sips6André Serra-Roma7Markus Weiss8Rambabu Danekula9Jan Rohr10Novartis Pharma AG, Basel, SwitzerlandDepartment of Rheumatology, Shanghai JiaoTong University School of Medicine, Shanghai, ChinaDepartment of Nephrology, Rheumatology and Kidney Transplantation, University Medical Center of the Johannes Gutenberg University, Mainz, GermanyNephrology Unit, Hospital General de Agudos Juan A Fernández, Buenos Aires, ArgentinaNovartis Pharma AG, Basel, SwitzerlandNovartis Pharma AG, Basel, SwitzerlandNovartis Pharma AG, Basel, SwitzerlandNovartis Pharma AG, Basel, SwitzerlandNovartis Pharma AG, Basel, SwitzerlandNovartis Pharma AG, Basel, SwitzerlandNovartis Pharma AG, Basel, SwitzerlandBackground Iscalimab (CFZ533) is a novel, anti-CD40 monoclonal antibody. This study evaluated the efficacy, pharmacokinetics and safety of iscalimab versus placebo as add-on to standard-of-care (SoC) therapy in patients with biopsy-proven active proliferative lupus nephritis (LN).Methods This was a phase II, randomised, double-blind, placebo-controlled, multicentre study including patients with a diagnosis of systemic lupus erythematosus with active LN. Patients were randomly assigned (2:1) to receive either intravenous iscalimab (10 mg/kg) or placebo for 24 weeks on top of SoC for LN. The primary efficacy endpoint was the ratio from baseline in urinary protein-to-creatinine ratio (UPCR) at week 24. Safety assessments included adverse events (AEs) and serious AEs (SAEs) during treatment and follow-up up to 49 weeks.Findings Of the 57 patients (iscalimab, n=39; placebo, n=18) randomised, 31 (54.4%) completed the study. The primary efficacy endpoint was met: at week 24, the relative improvement from baseline in proteinuria (UPCR) was 63.1% and 36.3% in the iscalimab and placebo arms, respectively. UPCR to baseline at week 24 showed a statistically significant reduction of 42.1% in the iscalimab versus placebo arm. Most AEs were of mild to moderate severity in both treatment arms. Overall, seven SAEs were reported in six patients (15.4%) in the iscalimab arm versus four in three patients (16.7%) in the placebo arm.Interpretation Iscalimab showed a significant improvement in proteinuria (UPCR) in patients with active LN. Iscalimab was generally well tolerated with the exception of a few severe infections and one case of macrophage-activation syndrome in immunosuppressed and comorbid patients.Trial registration number NCT03610516.https://rmdopen.bmj.com/content/11/3/e005557.full
spellingShingle Renaud Felten
Nan Shen
Julia Weinmann-Menke
Ana Malvar
Peter Gergely
Tamas Shisha
Carole Sips
André Serra-Roma
Markus Weiss
Rambabu Danekula
Jan Rohr
Efficacy, pharmacokinetics and safety of iscalimab (CFZ533) in patients with proliferative lupus nephritis: a randomised, double-blind, placebo-controlled, phase II study
RMD Open
title Efficacy, pharmacokinetics and safety of iscalimab (CFZ533) in patients with proliferative lupus nephritis: a randomised, double-blind, placebo-controlled, phase II study
title_full Efficacy, pharmacokinetics and safety of iscalimab (CFZ533) in patients with proliferative lupus nephritis: a randomised, double-blind, placebo-controlled, phase II study
title_fullStr Efficacy, pharmacokinetics and safety of iscalimab (CFZ533) in patients with proliferative lupus nephritis: a randomised, double-blind, placebo-controlled, phase II study
title_full_unstemmed Efficacy, pharmacokinetics and safety of iscalimab (CFZ533) in patients with proliferative lupus nephritis: a randomised, double-blind, placebo-controlled, phase II study
title_short Efficacy, pharmacokinetics and safety of iscalimab (CFZ533) in patients with proliferative lupus nephritis: a randomised, double-blind, placebo-controlled, phase II study
title_sort efficacy pharmacokinetics and safety of iscalimab cfz533 in patients with proliferative lupus nephritis a randomised double blind placebo controlled phase ii study
url https://rmdopen.bmj.com/content/11/3/e005557.full
work_keys_str_mv AT renaudfelten efficacypharmacokineticsandsafetyofiscalimabcfz533inpatientswithproliferativelupusnephritisarandomiseddoubleblindplacebocontrolledphaseiistudy
AT nanshen efficacypharmacokineticsandsafetyofiscalimabcfz533inpatientswithproliferativelupusnephritisarandomiseddoubleblindplacebocontrolledphaseiistudy
AT juliaweinmannmenke efficacypharmacokineticsandsafetyofiscalimabcfz533inpatientswithproliferativelupusnephritisarandomiseddoubleblindplacebocontrolledphaseiistudy
AT anamalvar efficacypharmacokineticsandsafetyofiscalimabcfz533inpatientswithproliferativelupusnephritisarandomiseddoubleblindplacebocontrolledphaseiistudy
AT petergergely efficacypharmacokineticsandsafetyofiscalimabcfz533inpatientswithproliferativelupusnephritisarandomiseddoubleblindplacebocontrolledphaseiistudy
AT tamasshisha efficacypharmacokineticsandsafetyofiscalimabcfz533inpatientswithproliferativelupusnephritisarandomiseddoubleblindplacebocontrolledphaseiistudy
AT carolesips efficacypharmacokineticsandsafetyofiscalimabcfz533inpatientswithproliferativelupusnephritisarandomiseddoubleblindplacebocontrolledphaseiistudy
AT andreserraroma efficacypharmacokineticsandsafetyofiscalimabcfz533inpatientswithproliferativelupusnephritisarandomiseddoubleblindplacebocontrolledphaseiistudy
AT markusweiss efficacypharmacokineticsandsafetyofiscalimabcfz533inpatientswithproliferativelupusnephritisarandomiseddoubleblindplacebocontrolledphaseiistudy
AT rambabudanekula efficacypharmacokineticsandsafetyofiscalimabcfz533inpatientswithproliferativelupusnephritisarandomiseddoubleblindplacebocontrolledphaseiistudy
AT janrohr efficacypharmacokineticsandsafetyofiscalimabcfz533inpatientswithproliferativelupusnephritisarandomiseddoubleblindplacebocontrolledphaseiistudy